UY34453A - Moléculas de unión para bcma y cd3 - Google Patents

Moléculas de unión para bcma y cd3

Info

Publication number
UY34453A
UY34453A UY34453A UY34453A UY34453A UY 34453 A UY34453 A UY 34453A UY 34453 A UY34453 A UY 34453A UY 34453 A UY34453 A UY 34453A UY 34453 A UY34453 A UY 34453A
Authority
UY
Uruguay
Prior art keywords
bcma
union
molecules
union molecules
escanear
Prior art date
Application number
UY34453A
Other languages
English (en)
Inventor
Borges Eric
Kufer Peter
Raum Tobias
Hoffmann Patrick
Kischel Roman
Lutterbuese Ralf
Rau Doris
Adam Paul
Hebeis Barbara
Hipp Susanne
Original Assignee
Boehringer Ingelheim Int
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47388493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34453(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int, Amgen Res Munich Gmbh filed Critical Boehringer Ingelheim Int
Publication of UY34453A publication Critical patent/UY34453A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Abstract

La presente invención se refiere a una molécula de unión que es al menos biespecífica, que comprende un primer y un segundo dominio de unión, en donde el primer dominio de unión es capaz de unirse al clúster de epítopes 3 de BCMA, y el segundo dominio de unión es capaz de unirse al complejo del receptor CD3 de células T. Más aún, la invención pro vee una secuencia de ácido nucleico que codifica la molécula de unión, un vector que comprende dicha secuencia de ácido nucleico y una célula hospedadora transformada o transfectada con dicho vector. Adicionalmente, la invención provee un proceso para la producción de la molécula de unión de la invención, un uso médico de dicha molécula de unión y un kit que comprende dicha molécula de unión.
UY34453A 2011-11-15 2012-11-15 Moléculas de unión para bcma y cd3 UY34453A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161560178P 2011-11-15 2011-11-15
US201161560149P 2011-11-15 2011-11-15
US201161560144P 2011-11-15 2011-11-15
US201161560183P 2011-11-15 2011-11-15
US201161560162P 2011-11-15 2011-11-15
US201261651486P 2012-05-24 2012-05-24
US201261651474P 2012-05-24 2012-05-24

Publications (1)

Publication Number Publication Date
UY34453A true UY34453A (es) 2013-06-28

Family

ID=47388493

Family Applications (2)

Application Number Title Priority Date Filing Date
UY34453A UY34453A (es) 2011-11-15 2012-11-15 Moléculas de unión para bcma y cd3
UY34454A UY34454A (es) 2011-11-15 2012-11-15 Moléculas de unión para bcma y cd3

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY34454A UY34454A (es) 2011-11-15 2012-11-15 Moléculas de unión para bcma y cd3

Country Status (39)

Country Link
US (7) US9150664B2 (es)
EP (4) EP2780375B1 (es)
JP (5) JP6378087B2 (es)
KR (4) KR20140105758A (es)
CN (3) CN109485729A (es)
AP (1) AP2014007529A0 (es)
AR (1) AR088883A1 (es)
AU (1) AU2012327203A1 (es)
BR (2) BR112014010630B1 (es)
CA (2) CA2849196C (es)
CL (1) CL2014001254A1 (es)
CY (1) CY1122543T1 (es)
DK (1) DK2780375T3 (es)
EA (2) EA028162B1 (es)
EC (2) ECSP14004829A (es)
ES (2) ES2749451T3 (es)
FR (1) FR23C1013I1 (es)
GE (1) GEP20186928B (es)
HR (1) HRP20191697T1 (es)
HU (1) HUE046682T2 (es)
IL (3) IL232603B (es)
LT (1) LT2780375T (es)
MA (2) MA35450B1 (es)
ME (1) ME03521B (es)
MX (2) MX349396B (es)
MY (1) MY189544A (es)
PE (1) PE20141564A1 (es)
PH (1) PH12014501091A1 (es)
PL (1) PL2780375T3 (es)
PT (1) PT2780375T (es)
RS (1) RS59373B1 (es)
SG (4) SG10201704483RA (es)
SI (1) SI2780375T1 (es)
TN (2) TN2014000097A1 (es)
TW (1) TWI679212B (es)
UA (1) UA116766C2 (es)
UY (2) UY34453A (es)
WO (2) WO2013072415A1 (es)
ZA (1) ZA201401615B (es)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX338038B (es) * 2008-10-01 2016-03-30 Amgen Res Munich Gmbh Anticuerpo de una sola cadena bis-especifico de pscaxcd3, cd19xcd3, c-metxcd3, endosialinaxcd3, epcamxcd3, igf-1rxcd3 o fapalfaxcd3 de especies cruzadas.
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
BR112014020826A8 (pt) 2012-02-24 2017-09-19 Stem Centrx Inc Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
ES2829499T3 (es) * 2013-02-05 2021-06-01 Engmab Sarl Método para la selección de anticuerpos contra BCMA
EP2762496A1 (en) * 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
RS58873B1 (sr) 2013-02-22 2019-08-30 Abbvie Stemcentrx Llc Antidll3-antitelo-pbd konjugati i njihova upotreba
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
ES2871418T3 (es) 2013-08-28 2021-10-28 Abbvie Stemcentrx Llc Composiciones y métodos de conjugación de anticuerpos específicos de sitio
DK3055327T3 (en) * 2013-10-09 2019-03-11 Res Found Dev Monoclonal OLFML-3 Antibodies and Uses thereof
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
GB201317928D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Molecule
ES2959480T3 (es) 2014-02-07 2024-02-26 Univ Mcmaster Acoplador de células T - antígeno trifuncional y métodos y usos del mismo
AU2015218633A1 (en) 2014-02-21 2016-09-01 Abbvie Stemcentrx Llc Anti-DLL3 antibodies and drug conjugates for use in melanoma
CA2939411A1 (en) * 2014-02-27 2015-09-03 Ucl Business Plc Ligand
AU2015248956B2 (en) * 2014-04-14 2020-06-25 Cellectis BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
JP2017520575A (ja) 2014-07-01 2017-07-27 ファイザー・インク 二重特異的ヘテロ二量体ダイアボディおよびその使用
EP2982692A1 (en) * 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
JP2017536341A (ja) * 2014-10-09 2017-12-07 エンクマフ アーゲー 卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
WO2016079081A1 (en) * 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Common light chains and methods of use
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
PL3227432T3 (pl) * 2014-12-05 2024-03-11 Memorial Sloan Kettering Cancer Center Chimeryczne receptory antygenowe ukierunkowane na antygen dojrzewania komórek b i ich zastosowania
KR20170108944A (ko) * 2014-12-05 2017-09-27 메모리얼 슬로안-케터링 캔서 센터 B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
EP3262424A4 (en) * 2015-02-24 2019-03-13 The University of British Columbia MICROFLUIDIC SYSTEM WITH CONTINUOUS FLOW
EP3757128A1 (en) 2015-04-13 2020-12-30 Pfizer Inc Chimeric antigen receptors targeting b-cell maturation antigen
BR112017019785B1 (pt) * 2015-04-13 2022-11-16 Pfizer Inc Anticorpo biespecífico, seu uso e composição farmacêutica
US11046767B2 (en) * 2015-05-13 2021-06-29 Ablynx N.V. T cell recruiting polypeptides based on CD3 reactivity
CA2986254A1 (en) 2015-05-18 2016-11-24 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
KR101997241B1 (ko) 2015-05-21 2019-07-09 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) * 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
US10683369B2 (en) * 2015-08-03 2020-06-16 Engmab Sàrl Monoclonal antibodies against BCMA
KR20180050321A (ko) 2015-08-07 2018-05-14 이미지냅 인코포레이티드 분자를 표적화하기 위한 항원 결합 구조체
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
DK3337824T3 (da) 2015-08-17 2020-08-24 Janssen Pharmaceutica Nv Anti-bcma-antistoffer, bispecifikke antigen-bindende molekyler, som binder bcma og cd3, og anvendelse deraf
AU2016325858B2 (en) 2015-09-24 2022-05-26 Daiichi Sankyo Company, Limited Anti-GARP antibody
WO2017091683A1 (en) 2015-11-25 2017-06-01 Visterra, Inc. Antibody molecules to april and uses thereof
TWI797073B (zh) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
EP3411404B1 (en) 2016-02-03 2022-11-09 Amgen Research (Munich) GmbH Psma and cd3 bispecific t cell engaging antibody constructs
BR112018015715A2 (pt) 2016-02-03 2019-02-05 Amgen Inc construtos de anticorpo de engate de célula t biespecífica bcma e cd3
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
ES2947230T3 (es) 2016-03-22 2023-08-03 Hoffmann La Roche Moléculas biespecíficas para linfocitos T activadas por proteasa
KR102591930B1 (ko) * 2016-04-01 2023-10-24 카이트 파마 인코포레이티드 Bcma 결합 분자 및 그의 사용 방법
JP7010491B2 (ja) 2016-04-11 2022-01-26 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク ヒト化抗ｒａｇｅ抗体
JP7042467B2 (ja) 2016-05-20 2022-03-28 ハープーン セラピューティクス，インク． 単鎖可変フラグメントｃｄ３結合タンパク質
BR112018073739A2 (pt) 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. proteína de ligação de albumina sérica de domínio único
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN109641049B (zh) 2016-06-21 2023-07-07 特尼奥生物股份有限公司 Cd3结合抗体
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
BR112019004873A2 (pt) * 2016-09-14 2019-06-11 Teneobio Inc anticorpos de ligação a cd3
MX2019003899A (es) 2016-10-07 2019-08-14 Tcr2 Therapeutics Inc Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CN110167964B (zh) 2016-11-02 2023-12-01 百时美施贵宝公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
CN110114371A (zh) * 2016-11-11 2019-08-09 奥托路斯有限公司 嵌合抗原受体
CN110177803A (zh) 2016-11-22 2019-08-27 T细胞受体治疗公司 用于使用融合蛋白进行tcr重新编程的组合物和方法
MX2019006045A (es) 2016-11-23 2019-11-11 Harpoon Therapeutics Inc Proteinas triespecificas dirigidas a psma y metodos de uso.
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
AU2017382251A1 (en) 2016-12-21 2019-07-11 Teneobio, Inc. Anti-BCMA heavy chain-only antibodies
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
KR20190115469A (ko) * 2017-02-10 2019-10-11 드래곤플라이 쎄라퓨틱스, 인크. Bcma, nkg2d 및 cd16에 결합하는 단백질
ES2949364T3 (es) 2017-02-17 2023-09-28 Fred Hutchinson Cancer Center Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA
WO2018158349A1 (en) 2017-02-28 2018-09-07 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3621648A4 (en) 2017-05-12 2021-01-20 Harpoon Therapeutics, Inc. TRISPECIFIC PROTEINS MSLN AND METHOD OF USE
US10543271B2 (en) 2017-05-12 2020-01-28 Harpoon Therapeutics, Inc. Mesothelin binding proteins
CN117567624A (zh) 2017-06-20 2024-02-20 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
KR20200018498A (ko) 2017-06-20 2020-02-19 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
HUE058233T2 (hu) 2017-08-03 2022-07-28 Amgen Inc Interleukin-21-muteinek és kezelési eljárások
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
TWI783890B (zh) 2017-08-24 2022-11-11 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
SG11202001499WA (en) 2017-09-08 2020-03-30 Amgen Inc Inhibitors of kras g12c and methods of using the same
JP2020533382A (ja) 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌の組合せ治療
WO2019053612A1 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited POLY THERAPY FOR THE TREATMENT OF CANCER
CN111094353A (zh) 2017-09-14 2020-05-01 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
CA3078637A1 (en) 2017-10-12 2019-04-18 Mcmaster University T cell-antigen coupler with y182t mutation and methods and uses thereof
US11136403B2 (en) * 2017-10-13 2021-10-05 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
EP3694871A4 (en) 2017-10-13 2021-11-10 Harpoon Therapeutics, Inc. B-CELL MATURATION ANTIG-BINDING PROTEINS
CN111629749A (zh) 2017-10-18 2020-09-04 诺华股份有限公司 用于选择性蛋白质降解的组合物和方法
EP3703688A2 (en) 2017-11-01 2020-09-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
KR20200116077A (ko) 2017-11-01 2020-10-08 주노 쎄러퓨티크스 인코퍼레이티드 B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
JP2021502979A (ja) 2017-11-15 2021-02-04 ノバルティス アーゲー Ｂｃｍａターゲティングキメラ抗原受容体、ｃｄ１９ターゲティングキメラ抗原受容体及び併用療法
US20200371091A1 (en) 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
US11873336B2 (en) 2017-12-22 2024-01-16 Teneobio, Inc. Heavy chain antibodies binding to CD22
KR20200104364A (ko) * 2017-12-27 2020-09-03 테네오바이오, 인코포레이티드 Cd3-델타/엡실론 이형이량체 특이적 항체
US11905327B2 (en) 2017-12-28 2024-02-20 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against TIGIT
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
CR20200330A (es) 2018-01-12 2020-12-23 Amgen Inc Anticuerpos anti-pd-1 y métodos de tratamiento
US11713353B2 (en) 2018-01-15 2023-08-01 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-1
AU2019211326A1 (en) * 2018-01-23 2020-09-10 Nextcure, Inc. B7-H4 antibodies and methods of use thereof
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
AU2019228128A1 (en) 2018-03-02 2020-09-03 Cdr-Life Ag Trispecific antigen binding proteins
CN116514995A (zh) * 2018-04-12 2023-08-01 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用
SG11202010064QA (en) * 2018-04-13 2020-11-27 Affimed Gmbh Nk cell engaging antibody fusion constructs
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
WO2019236684A1 (en) * 2018-06-08 2019-12-12 Imaginab, Inc. Antigen binding constructs to cd4
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
AU2019307928A1 (en) 2018-07-19 2021-02-11 Regeneron Pharmaceuticals, Inc. Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof
JP2021532073A (ja) 2018-07-31 2021-11-25 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｍａ−ｃｄ３二重特異性抗体のための投与レジメン
BR112021003305A2 (pt) 2018-08-31 2021-05-25 Novartis Ag métodos para produzir células que expressam receptor de antígeno quimérico
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
MX2021002190A (es) 2018-08-31 2021-05-14 Regeneron Pharma Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20.
JP7425049B2 (ja) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． Ｄｌｌ３結合タンパク質および使用方法
BR112021005669A2 (pt) 2018-09-28 2021-06-22 Amgen Inc. anticorpos contra bcma solúvel
CN109503716B (zh) * 2018-10-08 2021-04-27 浙江生研生物科技有限公司 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用
EP3874272A1 (en) 2018-10-31 2021-09-08 GlaxoSmithKline Intellectual Property Development Limited Methods of treating cancer
US20230416385A1 (en) * 2018-11-01 2023-12-28 Shandong New Time Pharmaceutical Co., Ltd. Bispecific antibody and use thereof
EP3930763A1 (en) 2019-02-25 2022-01-05 Novartis AG Mesoporous silica particles compositions for viral delivery
CN113597328A (zh) 2019-03-21 2021-11-02 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
US20230074800A1 (en) 2019-03-21 2023-03-09 Novartis Ag Car-t cell therapies with enhanced efficacy
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
CN114206927A (zh) 2019-06-14 2022-03-18 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
CA3144324A1 (en) * 2019-06-24 2020-12-30 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
CN112204135A (zh) * 2019-07-06 2021-01-08 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
WO2021004400A1 (zh) * 2019-07-06 2021-01-14 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
BR112022002236A2 (pt) 2019-08-06 2022-05-03 Glaxosmithkline Ip Dev Ltd Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas
CA3149585A1 (en) * 2019-09-25 2021-04-01 Bahram VALMEHR Multi-targeting effector cells and use thereof
EP3819007A1 (en) 2019-11-11 2021-05-12 Amgen Research (Munich) GmbH Dosing regimen for anti-bcma agents
AU2020393912A1 (en) 2019-11-26 2022-06-09 Novartis Ag Chimeric antigen receptors binding BCMA and CD19 and uses thereof
KR20220143037A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 Glp-1 조성물 및 이의 용도
EP4106806A1 (en) 2020-02-21 2022-12-28 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
JP2023515211A (ja) 2020-02-27 2023-04-12 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
MX2022010604A (es) 2020-02-27 2022-09-09 Novartis Ag Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
EP4121459A1 (en) 2020-03-19 2023-01-25 Amgen Inc. Antibodies against mucin 17 and uses thereof
WO2021222578A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
JP2023526774A (ja) 2020-04-29 2023-06-23 テネオバイオ， インコーポレイテッド 重鎖定常領域が修飾された多重特異性重鎖抗体
AU2021272291A1 (en) 2020-05-11 2023-02-02 Janssen Biotech, Inc. Methods for treating multiple myeloma
BR112022023392A2 (pt) 2020-05-19 2022-12-20 Janssen Biotech Inc Composições que compreendem um agente terapêutico de redirecionamento de células t e um inibidor da via de adesão de vla-4
IL298473A (en) 2020-06-11 2023-01-01 Novartis Ag zbtb32 inhibitors and uses thereof
AU2021300179A1 (en) 2020-06-30 2023-02-02 Teneobio, Inc. Multi-specific antibodies binding to BCMA
EP4199960A2 (en) 2020-08-21 2023-06-28 Novartis AG Compositions and methods for in vivo generation of car expressing cells
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
EP4243936A1 (en) 2020-11-10 2023-09-20 Amgen Inc. Methods for administering a bcma x cd3 binding molecule
CN114573703A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 一种t细胞衔接器治疗剂的开发和应用
WO2022135468A1 (zh) * 2020-12-23 2022-06-30 信达生物制药(苏州)有限公司 抗bcma×cd3双特异性抗体及其用途
CN114763383A (zh) * 2021-01-13 2022-07-19 博生吉医药科技(苏州)有限公司 靶向人bcma的单克隆抗体及其应用
JP2024506831A (ja) 2021-01-28 2024-02-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイトカイン放出症候群を治療するための組成物及び方法
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
WO2022229853A1 (en) 2021-04-27 2022-11-03 Novartis Ag Viral vector production system
BR112023024804A2 (pt) 2021-05-28 2024-02-15 Glaxosmithkline Ip Dev Ltd Terapias de combinação para tratar câncer
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
CA3227515A1 (en) 2021-08-03 2023-02-09 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions and stable isotope labeling peptide mapping method
WO2023021477A1 (en) 2021-08-20 2023-02-23 Novartis Ag Methods of making chimeric antigen receptor–expressing cells
CA3233953A1 (en) 2021-10-05 2023-04-13 Matthew Bruce Combination therapies for treating cancer
WO2023144702A1 (en) 2022-01-25 2023-08-03 Glaxosmithkline Intellectual Property Development Limited Combination therapy for cancer
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US567A (en) 1838-01-09 Machine for r-uibbii
US1985A (en) 1841-02-18 Charles m
US4816A (en) 1846-10-17 Bell machinery for hotels
US556A (en) 1838-01-09 Machine foe
US5013A (en) 1847-03-13 Improvement in apparatus for the manufacture of malleable iron
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
AU739331B2 (en) 1997-10-01 2001-10-11 Boston Scientific Limited Dilation systems and related methods
ES2203141T3 (es) 1998-04-21 2004-04-01 Micromet Ag Polipeptidos cd19 x cd3 especificos y su utilizacion.
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
IL144029A0 (en) 1999-01-07 2002-04-21 Zymogenetics Inc Soluble receptor br43x2 and methods of using
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
RS51157B (sr) 1999-08-17 2010-10-31 Biogen Idec Ma Inc. Baff receptor (bcma), imunoregulatorni agens
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2408617A1 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
CA2438682A1 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
RU2005137325A (ru) 2003-05-31 2006-09-10 Микромет Аг (De) Фармацевтическая композиция, содержащая конструкт, специфичный к ерсам
EP1673398B1 (en) 2003-10-16 2010-12-29 Micromet AG Multispecific deimmunized cd3-binders
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
WO2005075511A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
SI1716178T1 (sl) * 2004-02-16 2010-11-30 Micromet Ag Manj imunogene vezne molekule
CN101370830A (zh) * 2005-09-26 2009-02-18 米德列斯公司 抗cd70的人单克隆抗体
ES2856451T3 (es) 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
US20100183615A1 (en) * 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
JP2010524851A (ja) * 2007-04-03 2010-07-22 マイクロメット アーゲー 種間特異的結合ドメイン
EP4059964A1 (en) 2007-04-03 2022-09-21 Amgen Research (Munich) GmbH Cross-species-specific binding domain
CA2720682A1 (en) * 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
PL2352763T5 (pl) 2008-10-01 2023-01-30 Amgen Research (Munich) Gmbh Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej
US10981998B2 (en) * 2008-10-01 2021-04-20 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
CA2738565C (en) 2008-10-01 2023-10-10 Micromet Ag Cross-species-specific psmaxcd3 bispecific single chain antibody
MX338038B (es) 2008-10-01 2016-03-30 Amgen Res Munich Gmbh Anticuerpo de una sola cadena bis-especifico de pscaxcd3, cd19xcd3, c-metxcd3, endosialinaxcd3, epcamxcd3, igf-1rxcd3 o fapalfaxcd3 de especies cruzadas.
NZ612647A (en) 2009-03-10 2015-03-27 Biogen Idec Inc Anti-bcma antibodies
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
EP2640750A1 (en) 2010-11-16 2013-09-25 Boehringer Ingelheim International GmbH Agents and methods for treating diseases that correlate with bcma expression
EP4338754A2 (en) 2011-05-27 2024-03-20 Glaxo Group Limited Antigen binding proteins
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2731280B8 (en) 2012-11-07 2019-03-20 Telefonaktiebolaget LM Ericsson (publ) Loopback-based built-in-self-test
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
BR112018015715A2 (pt) * 2016-02-03 2019-02-05 Amgen Inc construtos de anticorpo de engate de célula t biespecífica bcma e cd3

Also Published As

Publication number Publication date
PT2780375T (pt) 2019-11-12
TW201326214A (zh) 2013-07-01
EP3623385A1 (en) 2020-03-18
EP3611193A1 (en) 2020-02-19
RS59373B1 (sr) 2019-11-29
ECSP14004829A (es) 2015-07-31
BR112014010940A2 (pt) 2017-05-16
GEP20186928B (en) 2018-11-26
CN104114578A (zh) 2014-10-22
CA2850591A1 (en) 2013-05-23
US20220064336A1 (en) 2022-03-03
EP2780375B1 (en) 2019-09-11
ES2749451T3 (es) 2020-03-20
IL232603A0 (en) 2014-06-30
KR102229469B1 (ko) 2021-03-18
TN2014000121A1 (en) 2015-07-01
CY1122543T1 (el) 2021-01-27
WO2013072415A1 (en) 2013-05-23
JP2018050627A (ja) 2018-04-05
PE20141564A1 (es) 2014-11-29
BR112014010630A2 (pt) 2017-04-25
EP2780374A1 (en) 2014-09-24
EP3623385A8 (en) 2020-05-06
KR20200003934A (ko) 2020-01-10
EA201490931A1 (ru) 2014-08-29
MA35449B1 (fr) 2014-09-01
JP2020202838A (ja) 2020-12-24
AP2014007529A0 (en) 2014-03-31
ES2751996T3 (es) 2020-04-02
US20220356268A1 (en) 2022-11-10
ME03521B (me) 2020-04-20
US10766969B2 (en) 2020-09-08
US20130156769A1 (en) 2013-06-20
UY34454A (es) 2013-06-28
SG11201400671YA (en) 2014-04-28
SG10201704483RA (en) 2017-07-28
US9598500B2 (en) 2017-03-21
US20130156770A1 (en) 2013-06-20
MA35450B1 (fr) 2014-09-01
WO2013072406A1 (en) 2013-05-23
CA2849196A1 (en) 2013-05-23
IL232603B (en) 2018-07-31
KR102062231B1 (ko) 2020-01-03
NZ622087A (en) 2016-06-24
US9150664B2 (en) 2015-10-06
BR112014010630B1 (pt) 2022-10-04
TWI679212B (zh) 2019-12-11
KR20210032012A (ko) 2021-03-23
EP2780374B1 (en) 2019-08-21
EA028162B1 (ru) 2017-10-31
ZA201401615B (en) 2017-08-30
CN109485729A (zh) 2019-03-19
AR088883A1 (es) 2014-07-16
EP2780375A1 (en) 2014-09-24
MX349396B (es) 2017-07-26
US20150023967A1 (en) 2015-01-22
JP2017195889A (ja) 2017-11-02
CN104169300A (zh) 2014-11-26
JP2014534242A (ja) 2014-12-18
FR23C1013I1 (fr) 2023-04-14
US20140348837A1 (en) 2014-11-27
MX2014005851A (es) 2015-01-19
EA201490932A1 (ru) 2014-09-30
KR20140105758A (ko) 2014-09-02
JP6378087B2 (ja) 2018-08-22
KR20140105757A (ko) 2014-09-02
US9340621B2 (en) 2016-05-17
SG11201401729PA (en) 2014-09-26
US20220251243A1 (en) 2022-08-11
UA116766C2 (uk) 2018-05-10
CA2849196C (en) 2021-04-20
MX2014005852A (es) 2014-09-22
SG10201606484SA (en) 2016-10-28
LT2780375T (lt) 2019-11-11
JP6231007B2 (ja) 2017-11-15
CN104114578B (zh) 2018-10-16
IL232636A0 (en) 2014-06-30
JP2015504306A (ja) 2015-02-12
KR102346029B1 (ko) 2022-01-03
AU2012327203A1 (en) 2013-05-30
SI2780375T1 (sl) 2019-11-29
MY189544A (en) 2022-02-16
JP6738314B2 (ja) 2020-08-12
DK2780375T3 (da) 2019-11-18
HRP20191697T1 (hr) 2019-12-13
HUE046682T2 (hu) 2020-03-30
CL2014001254A1 (es) 2014-10-10
ECSP14004893A (es) 2015-06-30
IL260189A (en) 2018-07-31
TN2014000097A1 (en) 2015-07-01
PL2780375T3 (pl) 2020-01-31
PH12014501091A1 (en) 2014-07-28
JP7250736B2 (ja) 2023-04-03

Similar Documents

Publication Publication Date Title
UY34454A (es) Moléculas de unión para bcma y cd3
CL2015002742A1 (es) Moléculas de unión para bcma y cd3.
UY34836A (es) Nuevo organismos
CO7350623A2 (es) Agentes moduladores de autotaxina (atx)
UY34456A (es) Anticuerpos anti-il-36r
UY34885A (es) Proteínas de unión anti-mesotelina
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
UY34587A (es) Formulaciones estabilizadas que contienen anticuerpos antiang2
UY34817A (es) Tienopirimidinas
CO7091177A2 (es) Inhibidores de la beta-secretasa
BR112014001219A2 (pt) perfume
UY34582A (es) Anticuerpos anti-cxcr3
UY34027A (es) Inhibidores sustituidos de acetil-coa carboxilasa.
UY34167A (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
UY4210Q (es) Silla
BR112014026634A2 (pt) direcionador
UY4153Q (es) Batería
BR112013024363A2 (pt) método, e aparelho
BR112014027219A2 (pt) método
UY4152Q (es) Batería
BR112013025764A2 (pt) dispositivo impulsionador
UY4247Q (es) Silla
UY4189Q (es) Exhibidor para mostrador
TN2011000372A1 (fr) جهاز مراقبة وتحكم في استهلاك المياه
TN2011000399A1 (fr) دراجة كهربائية ذات شحن الي

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20221101